# US 2020/0206279 A1 · Ammonia oxidizing microorganisms for use and delivery to the urogenital system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206279 A1
- Document ID: US20200206279A1
- Status: Published application
- Kind: A1
- Application number: 16/631,776
- Filed: 2018-07-17
- Published: 2020-07-02
- Earliest claimed: 2017-07-18
- Assignees: Aobiome LLC
- Applicants: Aobiome LLC
- Inventors: Lauren Nicole Ambrogio; Larry Weiss
- Web page: https://patentgrep.com/patent/US20200206279A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0036: {Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}
- A61K 9/0039: {Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- A61P 15/10: for impotence
- A61Q 19/00: Preparations for care of the skin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Ammonia oxidizing microorganism preparations for delivery to the urogenital system, kits including ammonia oxidizing preparations for delivery to the urogenital system, and devices for administering ammonia oxidizing preparations to the urogenital system are provided. Methods of introducing ammonia oxidizing microorganisms to the urogenital system are provided. Methods of treating disorders, including urogenital disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

## Claims

### Claim 1

A method of introducing ammonia oxidizing microorganisms (AOM) to a subject, comprising:
administering a preparation comprising AOM to a urogenital system of the subject.

### Claim 2

A method of introducing AOM to a subject, comprising:
rectally administering an effective amount of a preparation comprising AOM to the subject.

### Claim 3

A method of introducing AOM to a subject, comprising:
vaginally administering an effective amount of a preparation comprising AOM to the subject.

### Claim 4

A method of introducing AOM to a subject, comprising:
administering an effective amount of a preparation comprising AOM to the subject via catheterization.

### Claim 5

A method of populating a birth canal of a subject with AOM, comprising:
introducing an effective amount of a preparation comprising AOM to the birth canal of the subject,
thereby populating the birth canal with AOM.

### Claim 6

The method of any of the preceding claims, wherein administration is associated with the placement or removal of a urogenital device, or with the collection or manipulation of urogenital tissue.

### Claim 7

The method of any of the preceding claims, wherein administration is associated with a fecal microbiota transplant procedure.

### Claim 8

The method of any of the preceding claims, wherein a target percentage of administered AOM are transferred to the urogenital system of the subject.

### Claim 9

The method of any of the preceding claims, wherein the preparation is administered, e.g., topically applied or rectally applied, to a first tissue, e.g. a deposit tissue.

### Claim 10

The method of any of the preceding claims, wherein the first tissue is the target tissue.

### Claim 11

The method of any of the preceding claims, wherein the first tissue is other than the target tissue, e.g., the preparation is applied to a first tissue and the preparation, or a product of the preparation, e.g., NO, is transported, e.g., by diffusion, to a second tissue, e.g. the target tissue.

### Claim 12

The method of any of the preceding claims, wherein the deposit tissue, target tissue, or both comprises a urogenital cavity of the subject.

### Claim 13

The method of any of the preceding claims, wherein the deposit tissue, target tissue, or both relates to a reproductive organ of the subject.

### Claim 14

The method of any of the preceding claims, wherein the deposit tissue, target tissue, or both relates to an excretory organ of the subject.

### Claim 15

The method of any of the preceding claims, wherein the deposit tissue, target tissue, or both is a mucous membrane of the subject.

### Claim 16

The method of any of the preceding claims, wherein the target tissue comprises a rectal target tissue including superficial tissues, e.g. buttocks, anus, and the areas surrounding the anus, internal tissues, e.g. rectum, colon, large intestine, small intestine, and anal sphincter muscles; and proximate tissues, e.g. perineum, pelvic floor muscles and prostate.

### Claim 17

The method of any of the preceding claims, wherein the target tissue comprises a target urethral tissue including urethra, external urethral sphincter, urogenital diaphragm, bladder, ureter orifices, bladder mucosa and sub-mucosa, detrusor muscle, peritoneum, rugae, ureter, corpus spongiosum, corpus cavernosum, spongy urethra, membranous urethra, bulbourethral gland, prostate gland, prostatic urethra, vas deferens, ejaculatory duct, seminal vesicle, or ampulla of ductus deferens.

### Claim 18

The method of any of the preceding claims, wherein the target tissue comprises penile tissue, scrotum tissue, epididymis tissue, or testes.

### Claim 19

The method of any of the preceding claims, wherein the target tissues comprises a vaginal target tissue including labia majora, labia minora, surrounding vaginal superficial tissues, vagina, cervix, uterus, fallopian tubes, and ovaries.

### Claim 20

The method of any of the preceding claims, wherein the target tissue is associated with a desired local effect.

### Claim 21

The method of any of the preceding claims, wherein the desired local effect involves treatment of a urogenital condition including bacterial infections, e.g., bacterial vaginosis, fungal infections, e.g., tinea unguium, itching, local inflammation, e.g., keratosis pilaris, pemphigus, proctitis, folliculitis, hidradenitis suppurativa, dermatomyositis, hemorrhoid, diaper rash, razor burn, intraurogenital inflammation, viral infections, e.g., infections caused by human papillomavirus (HPV), erectile dysfunction, body odor, feminine odor, heloma, pH imbalance, hemorrhoid, fibroid, inflammation associated with an implant, or wound healing.

### Claim 22

The method of any of the preceding claims, wherein the target tissue is associated with a desired systemic effect.

### Claim 23

The method of any of the preceding claims, wherein the desired systemic effect involves treatment of one or more of headaches, cardiovascular diseases, inflammation, immune responses and autoimmune disorders, liver diseases, infections, neurological diseases, psychiatric disorders, nitric oxide disorders, urea cycle disorders, congestion, vasodilation disorders, skin diseases, wound healing, reactions to insect bites, ophthalmic disorders, connective tissue disorders, pH imbalance, and certain viral, bacterial, and fungal, e.g., yeast, infections.

### Claim 24

The method of any of the preceding claims, wherein administering the effective amount of the preparation promotes endothelial function.

### Claim 25

The method of any of the preceding claims, wherein administering the effective amount of the preparation changes or alters a level of nitrite or NO at the target tissue or systemically.

### Claim 26

The method of any of the preceding claims, wherein administering the effective amount of the preparation modulates a microbiome associated with the urogenital system of the subject.

### Claim 27

A method of treating a urogenital condition in a subject, comprising:
administering an effective amount of a preparation comprising AOM to the subject,
thereby treating the urogenital condition.

### Claim 28

The method of any of the preceding claims, wherein administering comprises topical, vaginal, urethral, or rectal administration.

### Claim 29

The method of any of the preceding claims, wherein administering is device-assisted.

### Claim 30

The method of any of the preceding claims, wherein the urogenital condition comprises an inflammatory condition.

### Claim 31

The method of any of the preceding claims, wherein the urogenital condition comprises a bacterial, fungal, or viral infection.

### Claim 32

The method of any of the preceding claims, wherein the urogenital condition comprises sexual dysfunction.

### Claim 33

The method of any of the preceding claims, wherein the preparation is administered prior to onset of a urogenital condition.

### Claim 34

The method of any of the preceding claims, wherein the preparation is administered during incidence of a urogenital condition.

### Claim 35

The method of any of the preceding claims, wherein the preparation is administered subsequent to the subsiding of a urogenital condition.

### Claim 36

The method of any of the preceding claims, wherein the preparation is administered in response to a urogenital symptom, trigger, or warning sign.

### Claim 37

The method of any of the preceding claims, further comprising determining whether the subject is in need of treatment for a urogenital condition.

### Claim 38

The method of any of the preceding claims, wherein the preparation is administered as a solution, liquid, ointment, gel, hydrogel, suspension, emulsion, foam, insert, capsule, suppository, pessary, film, vaginal ring, catheter, stent, or intrauterine device.

### Claim 39

The method of any of the preceding claims, wherein the preparation is administered as an enema, douche, wash, spray, aerosol, or mist.

### Claim 40

The method of any of the preceding claims, wherein the preparation is formulated to be compatible with the urogenital system of the subject.

### Claim 41

The method of any of the preceding claims, wherein the preparation has a substantially physiological pH level.

### Claim 42

The method of any of the preceding claims, wherein the preparation is formulated for immediate release or extended release.

### Claim 43

The method of any of the preceding claims, wherein the preparation is formulated to deliver nitrite or NO to the target tissue or systemically.

### Claim 44

The method of any of the preceding claims, wherein the preparation is formulated for transmucosal delivery and/or circulation, e.g. locally or systemically.

### Claim 45

The method of any of the preceding claims, further comprising administering a second amount of the preparation to the subject.

### Claim 46

The method of any of the preceding claims, wherein the preparation is administered as part of a combination therapy.

### Claim 47

The method of any of the preceding claims, further comprising administering a second treatment in combination with the preparation.

### Claim 48

The method of any of the preceding claims, wherein the second treatment comprises a surgical procedure.

### Claim 49

The method of any of the preceding claims, wherein the preparation is administered before or after a surgical or diagnostic procedure, e.g., a colonoscopy, endoscopy, or colposcopy.

### Claim 50

The method of any of the preceding claims, wherein the preparation is administered for a period of time prior to initiating the second treatment.

### Claim 51

The method of any of the preceding claims, wherein the preparation is administered concurrently with the second treatment.

### Claim 52

The method of any of the preceding claims, wherein the preparation is administered for a period of time subsequent to ceasing the second treatment.

### Claim 53

The method of any of the preceding claims, wherein the second treatment is administered via an alternate mode of administration, e.g. orally.

### Claim 54

The method of any of the preceding claims, wherein the subject has a therapeutic level of a second treatment.

### Claim 55

The method of any of the preceding claims, wherein the preparation is administered in conjunction with an anti-inflammatory agent.

### Claim 56

The method of any of the preceding claims, wherein the preparation is administered in conjunction with a medical approach that treats, e.g., is approved to treat or is commonly used to treat, the relevant disease or disorder, or a symptom of the relevant disease or disorder.

### Claim 57

The method of any of the preceding claims, wherein the preparation is administered in conjunction with a birth control method or a bacterial or fungal infection, e.g., yeast infection, treatment.

### Claim 58

The method of any of the preceding claims, wherein the preparation is administered in combination with antibiotics, diabetes medication, treatment to strengthen the immune system, hormone therapy, treatment of menopausal symptoms, treatment of menstrual symptoms, anti- stress therapies, or sleep aids.

### Claim 59

The method of any of the preceding claims, wherein the preparation is administered in conjunction with nitrite, nitrate, and/or NO.

### Claim 60

The method of any of the preceding claims, wherein the effective amount is a therapeutically effective dose of AOM.

### Claim 61

The method of any of the preceding claims, wherein the therapeutically effective dose of AOM is about or greater than about 1×103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 CFU.

### Claim 62

The method of any of the preceding claims, wherein the preparation is administered as an analgesic.

### Claim 63

The method of any of the preceding claims, wherein the preparation is administered as a prophylactic.

### Claim 64

The method of any of the preceding claims, wherein the preparation is self-administered.

### Claim 65

The method of any of the preceding claims, wherein the preparation is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per day.

### Claim 66

The method of any of the preceding claims, wherein the preparation is administered for about 1-3, 3-5, 5-7, 7-9, 5-10, 10-14, 12-18, 12-21, 21-28, 28-35, 35-42, 42-49, 49-56, 46-63, 63-70, 70-77, 77-84, or 84-91 days.

### Claim 67

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject waking from sleep.

### Claim 68

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes prior to the subject sleeping.

### Claim 69

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject eating.

### Claim 70

The method of any of the preceding claims, wherein the preparation is administered 30, 60, 90, 120, 150, or 180 minutes before the subject cleanses or showers.

### Claim 71

The method of any of the preceding claims, wherein the subject is female.

### Claim 72

The method of any of the preceding claims, wherein the subject is male.

### Claim 73

The method of any of the preceding claims, wherein the subject is characterized as one of the following ethnicity/race: Asian, black or African American, Hispanic or Latino, white, or multi-racial.

### Claim 74

The method of any of the preceding claims, wherein the subject is of an age of less than 1 or between 1-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, or over 60 years.

### Claim 75

The method of any of the preceding claims, wherein the subject has a disrupted microbiome.

### Claim 76

The method of any of the preceding claims, wherein the preparation comprises AOM in a buffer solution, e.g., an aqueous buffer solution.

### Claim 77

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 78

The method of any of the preceding claims, wherein the buffer solution e.g., aqueous buffer solution, consisting essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 79

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, consists of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 80

The method of any of the preceding claims, wherein the preparation further comprises or is administered concurrently with a compound that promotes growth or metabolism of the AOM, NO production, and/or urease activity.

### Claim 81

The method of any of the preceding claims, wherein the preparation comprises at least one of ammonia, ammonium salts, and urea.

### Claim 82

The method of any of the preceding claims, wherein the preparation comprises a controlled release material, e.g., slow release material.

### Claim 83

The method of any of the preceding claims, wherein the preparation further comprises an excipient, e.g., a pharmaceutically acceptable excipient.

### Claim 84

The method of any of the preceding claims, wherein the excipient comprises absorption and penetration enhancers, analgesics, local analgesics, antifungal agents, anti-inflammatory agents, steroids and corticosteroids, thermoreversible gels, preservatives, antioxidants, buffers, chelating agents, ion exchange agents, solubilizing agents, suspending agents, thickeners, surfactants, wetting agents, tonicity-adjusting agents, or a vehicle for proper drug delivery.

### Claim 85

The method of any of the preceding claims, wherein the preparation comprises a mucoadhesive agent.

### Claim 86

The method of any of the preceding claims, wherein the preparation includes a disintegrant, chelator, coating agent, modified-release product, or filler.

### Claim 87

The method of any of the preceding claims, wherein the preparation is substantially free of other organisms.

### Claim 88

The method of any of the preceding claims, wherein the preparation comprises between about 1×103 CFU/mL to about 1×1014 CFU/mL AOM.

### Claim 89

The method of any of the preceding claims, wherein the preparation comprises between about 1×109 CFU/mL to about 10×109 CFU/mL AOM.

### Claim 90

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing bacteria (AOB).

### Claim 91

The method of any of the preceding claims, wherein the AOM consist essentially of AOB.

### Claim 92

The method of any of the preceding claims, wherein the AOM consist of AOB.

### Claim 93

The method of any of the preceding claims, wherein the AOM comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio, and combinations thereof.

### Claim 94

The method of any of the preceding claims, wherein the AOM is Nitrosomonas eutropha (N. eutropha).

### Claim 95

The method of any of the preceding claims, wherein the AOM is N. eutropha D23, having ATCC accession number PTA-121157.

### Claim 96

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing archaea (AOA).

### Claim 97

The method of any of the preceding claims, wherein the AOM are capable of converting ammonia or ammonium to nitrite at a rate of at least about 1 pmol/min/mg protein, e.g., at least about 0.1 nmol/min/mg protein.

### Claim 98

The method of any of the preceding claims, wherein a biome-friendly product is used in connection with the administered preparation comprising AOM.

### Claim 99

A preparation comprising AOM, as recited in any of the preceding claims, for urogenital administration to a subject.

### Claim 100

A preparation comprising AOM, as recited in any of the preceding claims, for rectal administration to a subject

### Claim 101

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of a urogenital condition in a subject.

### Claim 102

The preparation of any of the preceding claims, formulated for vaginal or urethral delivery.

### Claim 103

The preparation of any of the preceding claims, wherein the preparation is packaged for single use.

### Claim 104

The preparation of any of the preceding claims, wherein the preparation is packaged for multiple use.

### Claim 105

The preparation of any of the preceding claims, comprising AOM and other organisms, e.g., a community of organisms.

### Claim 106

A device configured to administer a preparation comprising AOM, as recited in any of the preceding claims, to a deposit or target tissue of a urogenital system of a subject.

### Claim 107

The device of any of the preceding claims, wherein the device is an implantable device.

### Claim 108

The device of any of the preceding claims, wherein the device is an IUD or a vaginal ring.

### Claim 109

The device of any of the preceding claims, configured for vaginal or urethral delivery.

### Claim 110

The device of any of the preceding claims, wherein the device is a catheter.

### Claim 111

A kit comprising a preparation comprising AOM as recited in any of the preceding claims.
